"Coeus Invest Oy is a Finnish investment company founded in 2021. The company’s founders are two passionate investors, Jens Kyllönen and @Arimatti_Alhanko. Coeus Invest Oy’s analyses, experience, and investment philosophy are utilized in the Coeus Invest GRIT special investment fund.
The goal of Coeus Invest Oy’s investment philosophy is to achieve high absolute returns over the long term, significantly outperforming the market. To achieve this, we cannot do things the same way as others. Our investment philosophy differs from others:
- Capital concentration
- Small and medium-sized companies
- Home-field advantage
- Long investment horizon
- Passion
The year has been challenging in terms of returns: “The fund’s value decreased by 14.28 percent1 between July 1 and September 30, 2022, and by 30.48 percent2 since the fund’s inception in January. At the end of the third quarter of 2022, the fund held 11 positions, and approximately 13 percent of the fund’s portfolio was in cash. The fund’s five largest holdings at the end of the review period, in order of size, were Stockmann, Evolution, Kamux, OmaSp, and Upsales.”
In the Q3 investor letter, they described how quickly they reacted to changes in companies/the market:
"Excessive trading is not part of our investment strategy. However, an exceptional year has led us to make several larger strategic moves, each of which has been successful so far. As we wrote in the investor letter dated April 14, 2022, the Fund significantly reduced its weighting in Harvia when the war in Ukraine broke out. The Fund continued to reduce its position in the company throughout the summer, and by the time of the negative profit warning published on July 19, 2022, the stock’s weighting in the Fund was only about one percent. Immediately after the negative profit warning, the Fund sold the remaining Harvia shares at a price of approximately 25.4 euros. Since that day, Harvia’s share price has fallen by another 45%.
We mentioned in the investor letter dated July 9, 2022, that the Fund had completely sold off Remedy. Remedy’s share price has fallen by 30% since the most recent sales. Just before Tecnotree’s Q2 interim report, the Fund decided to sell all Tecnotree shares. The stock has fallen by 45% since the most recent sales.
Based on Kamux’s July sales statistics and competitors’ interim reports, we considered it highly likely that the company would issue a negative profit warning. As a result, the Fund began to reduce its Kamux holding as liquidity allowed. The negative profit warning came on August 11, and the Fund had managed to reduce its Kamux position by approximately 35%. The share price fell by about 15% with the negative profit warning, after which the Fund bought back the shares it had sold and continued to increase its Kamux holding throughout August."
I am very close to subscribing, but I would like to hear other people’s experiences and opinions on the fund. Kyllönen and Alhanko truly seem like passionate investors with the skill and courage to make good investment decisions.
Are there any fund owners here? What views are there for and against investing in the fund?